EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is it Worth The Risk?
Crossref DOI link: https://doi.org/10.1007/s12253-019-00599-z
Published Online: 2019-01-19
Published Print: 2019-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mormile, Raffaella
Text and Data Mining valid from 2019-01-19
Article History
Received: 7 September 2018
Accepted: 15 January 2019
First Online: 19 January 2019
Compliance with Ethical Standards
:
: The author declares no conflict of interest.